MORAb-202
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Nov 14, 2022 → Aug 12, 2024
NCT ID
NCT05577715About MORAb-202
MORAb-202 is a phase 2 stage product being developed by Eisai for Carcinoma, Non-Small-Cell Lung. The current trial status is terminated. This product is registered under clinical trial identifier NCT05577715. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05577715 | Phase 2 | Terminated |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung